Carcinoma — Variants & evidence

Carcinoma — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

2,354 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 2,351–2,354 of 2,354 evidence items (4 on this page mapped to a descendant entity) · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
XRCC1 R194W1
Docetaxel + Gemcitabine + VinorelbineSubstitutes	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID659 The XRCC1 R194W variant was shown to be correlated with increased chance of response to platinum-based chemotherapy in Stage IV Non-small Cell Lung Carcinoma (NSCLC). 82 patients with Stage IV NSCLC w… (full text at CIViC) PMID 19157633 · Sun et al., 2009 · Open in CIViC	civic
ORC1 Mutation + XRCC3 MutationXRCC3 ORC11
Cisplatin	Triple-Negative Breast CarcinomaALIAS	Predictive	D	Supports Sensitivity Response	3	submitted	EID11716 In this study, the sensitivity to Cisplatin (a platinum-based drug) was studied in XRCC3 knockout, and ORC1 mutant PDX models. A role of XRCC3 loss in cisplatin sensitivity was reported in the study. … (full text at CIViC) PMID 37029129 · Ter Brugge et al., 2023 · Open in CIViC	civic
YES1 Amplification + YES1 Overexpression1
CH6953755 + DasatinibSubstitutes	Lung Small Cell Carcinoma	Predictive	D	Supports Sensitivity Response	2	submitted	EID12556 In preclinical small cell lung carcinoma (SCLC) models with YES1 amplification or high expression, treatment with the YES1 inhibitor CH6953755 (30 mg/kg, q2d) or dasatinib (45 mg/kg daily) produced ma… (full text at CIViC) PMID 35988891 · Redin et al., 2022 · Open in CIViC	civic
ZHX2 Overexpression1
Sorafenib	Papillary Renal Cell Carcinoma	Predictive	C	Supports Sensitivity Response	3	submitted	EID9114 Efficacy of second-line sorafenib treatment (initially 12.5 mg/day, escalated to 25 mg/day) in a 82-year old male patient with type 2 papillary renal cell carcinoma was confirmed with a partial respon… (full text at CIViC) PMID 32743370 · Morinaga et al., 2019 · Open in CIViC	civic

Data updated 16 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.